Compare ONCO & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONCO | GCTK |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.5M |
| IPO Year | 2021 | 2011 |
| Metric | ONCO | GCTK |
|---|---|---|
| Price | $0.81 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 192.6K | ★ 17.6M |
| Earning Date | 06-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.80 | N/A |
| EPS | N/A | ★ 2.65 |
| Revenue | ★ $815,371.00 | $589,462.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $0.25 |
| 52 Week High | $6.73 | $14.14 |
| Indicator | ONCO | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 46.86 |
| Support Level | $0.62 | $0.28 |
| Resistance Level | $0.86 | $0.68 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 47.82 | 19.37 |
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.